PL3733665T3 - Związki zawierające ugrupowanie 2-okso-1,3,4-tiadiazynan-3-ylowe mające aktywność agonisty receptora EP4 - Google Patents

Związki zawierające ugrupowanie 2-okso-1,3,4-tiadiazynan-3-ylowe mające aktywność agonisty receptora EP4

Info

Publication number
PL3733665T3
PL3733665T3 PL18893819.5T PL18893819T PL3733665T3 PL 3733665 T3 PL3733665 T3 PL 3733665T3 PL 18893819 T PL18893819 T PL 18893819T PL 3733665 T3 PL3733665 T3 PL 3733665T3
Authority
PL
Poland
Prior art keywords
thiadiazinan
oxo
containing compounds
receptor agonist
agonist activity
Prior art date
Application number
PL18893819.5T
Other languages
English (en)
Inventor
Daisuke Shikanai
Noriko ISHIGURO
Osamu Omori
Original Assignee
Asahi Kasei Pharma Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Kasei Pharma Corporation filed Critical Asahi Kasei Pharma Corporation
Publication of PL3733665T3 publication Critical patent/PL3733665T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL18893819.5T 2017-12-25 2018-12-25 Związki zawierające ugrupowanie 2-okso-1,3,4-tiadiazynan-3-ylowe mające aktywność agonisty receptora EP4 PL3733665T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017248173 2017-12-25
PCT/JP2018/047450 WO2019131582A1 (ja) 2017-12-25 2018-12-25 含窒素6員環化合物

Publications (1)

Publication Number Publication Date
PL3733665T3 true PL3733665T3 (pl) 2023-02-06

Family

ID=67063663

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18893819.5T PL3733665T3 (pl) 2017-12-25 2018-12-25 Związki zawierające ugrupowanie 2-okso-1,3,4-tiadiazynan-3-ylowe mające aktywność agonisty receptora EP4

Country Status (13)

Country Link
US (2) US10988468B2 (pl)
EP (1) EP3733665B1 (pl)
JP (1) JP6896106B2 (pl)
KR (1) KR102446027B1 (pl)
CN (1) CN111511736B (pl)
AU (1) AU2018396402C1 (pl)
CA (1) CA3086662C (pl)
ES (1) ES2929799T3 (pl)
MX (1) MX2020006307A (pl)
PH (1) PH12020500556A1 (pl)
PL (1) PL3733665T3 (pl)
PT (1) PT3733665T (pl)
WO (1) WO2019131582A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3733665T3 (pl) * 2017-12-25 2023-02-06 Asahi Kasei Pharma Corporation Związki zawierające ugrupowanie 2-okso-1,3,4-tiadiazynan-3-ylowe mające aktywność agonisty receptora EP4
US11471508B2 (en) 2019-05-09 2022-10-18 The Feinstein Institutes For Medical Research HMGB1 antagonist treatment of diabetic peripheral neuropathy
IL322277A (en) 2019-05-09 2025-09-01 Feinstein Institutes For Medical Research Thio-semicarbazide compounds and their use
US11883461B2 (en) 2019-05-09 2024-01-30 The Feinstein Institutes For Medical Research HMGB1 antagonist treatment of severe sepsis
CN111440141A (zh) * 2020-05-20 2020-07-24 安徽泽升科技有限公司 一种羟甲基取代芳杂环类化合物的制备方法
CN111718353B (zh) * 2020-08-04 2023-02-10 许昌恒生制药有限公司 一种磷酸西格列汀的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001290250A1 (en) 2000-09-21 2002-04-02 Ono Pharmaceutical Co. Ltd. Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient
EA200300379A1 (ru) * 2000-11-27 2003-08-28 Пфайзер Продактс Инк. Селективные агонисты рецептора ep4 в лечении остеопороза
PL215425B1 (pl) 2001-07-16 2013-12-31 Ono Pharmaceutical Co Pochodna pirolidonu, srodek farmaceutyczny zawierajacy te pochodna i jej zastosowanie
JP4273407B2 (ja) 2001-07-23 2009-06-03 小野薬品工業株式会社 Ep4アゴニストを有効成分とする骨量低下疾患の治療剤
AU2002340282B2 (en) 2001-10-23 2007-08-09 Merck Serono Sa Pyrazolidinone compounds as ligands of the prostaglandin EP2 and/or EP4 receptors
US7053085B2 (en) 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
CA2511255C (en) 2003-01-10 2009-04-07 F. Hoffmann-La Roche Ag 2-piperidone derivatives as prostaglandin agonists
US6747037B1 (en) 2003-06-06 2004-06-08 Allergan, Inc. Piperidinyl prostaglandin E analogs
WO2005053707A1 (ja) 2003-12-05 2005-06-16 Ono Pharmaceutical Co., Ltd. 馬尾神経組織血流増加剤
US7858610B2 (en) 2004-08-10 2010-12-28 Ono Pharmaceutical Co., Ltd. Preventive and/or remedy for lower urinary tract diseases containing EP4 agonist
US7531533B2 (en) 2005-01-27 2009-05-12 Asahi Kasei Pharma Corporation 6-Membered heterocyclic compound and use thereof
CA2596003C (en) * 2005-01-27 2012-12-18 Asahi Kasei Pharma Corporation Six-membered heterocyclic compound and use thereof
JP5040650B2 (ja) 2005-06-03 2012-10-03 小野薬品工業株式会社 神経再生および/または保護剤
EP1912957A4 (en) * 2005-08-03 2009-05-13 Merck Frosst Canada Ltd EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS
EP1912977A4 (en) * 2005-08-03 2009-10-21 Merck Frosst Canada Ltd EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS
PT2989098T (pt) 2013-03-15 2017-08-16 Cayman Chemical Co Inc Compostos de lactama como agonistas selectivos do receptor ep4 para uso no tratamento de doenças e condições mediadas por ep4
PL3733665T3 (pl) * 2017-12-25 2023-02-06 Asahi Kasei Pharma Corporation Związki zawierające ugrupowanie 2-okso-1,3,4-tiadiazynan-3-ylowe mające aktywność agonisty receptora EP4

Also Published As

Publication number Publication date
US10988468B2 (en) 2021-04-27
JP6896106B2 (ja) 2021-06-30
RU2020120817A3 (pl) 2022-01-27
AU2018396402C1 (en) 2021-03-18
EP3733665B1 (en) 2022-09-28
US20210188837A1 (en) 2021-06-24
MX2020006307A (es) 2020-09-17
AU2018396402A1 (en) 2020-07-09
US20200347046A1 (en) 2020-11-05
US11667630B2 (en) 2023-06-06
CN111511736B (zh) 2023-03-24
WO2019131582A1 (ja) 2019-07-04
KR20200073265A (ko) 2020-06-23
CA3086662C (en) 2022-01-25
CN111511736A (zh) 2020-08-07
CA3086662A1 (en) 2019-07-04
EP3733665A1 (en) 2020-11-04
PT3733665T (pt) 2022-10-21
PH12020500556A1 (en) 2021-04-19
AU2018396402B2 (en) 2020-10-29
RU2020120817A (ru) 2022-01-27
ES2929799T3 (es) 2022-12-01
EP3733665A4 (en) 2021-06-02
KR102446027B1 (ko) 2022-09-21
JPWO2019131582A1 (ja) 2021-01-14
BR112020012405A2 (pt) 2020-11-24

Similar Documents

Publication Publication Date Title
IL272056A (en) Heterocyclic compounds as adenosine antagonists
ZA201807351B (en) Novel gpr119 agonist compounds
IL276400A (en) Dopamine D3 receptor antagonist compounds
LT3193880T (lt) Pereinamojo receptoriaus potencialo a1 jonų kanalo slopinimas
IL284767A (en) Heterocyclic compounds as adenosine antagonists
EP3038466A4 (en) 2,2-difluorodioxolo a2a receptor antagonists
IL255937B (en) Heterocyclic compounds 3,3-difluoropiperidine carbamate as nr2b nmda receptor antagonists
HK1250029A1 (zh) 具有双环结构的多巴胺d3受体拮抗剂
LT3134410T (lt) Pereinamojo receptoriaus potencialo a1 jonų kanalo slopinimas
IL253848A0 (en) Amine compounds as 5-hydroxytryptamine 4 receptor agonists
SG11202001340VA (en) Quinoxaline derivatives as adenosine receptor antagonists
HUE048865T2 (hu) Fenilszármazékok 2-es típusú kannabinoid receptor agonistaként
IT201700038155U1 (it) Trasportino per animali domestici
IL284762A (en) Heterocyclic compounds as adenosine antagonists
EP3112362A4 (en) Compound exhibiting selective ep2 agonist activity
SG11202104081XA (en) 5-azaindazole derivatives as adenosine receptor antagonists
SG11202000823WA (en) Thiazolopyridine derivatives as adenosine receptor antagonists
SG11202104078PA (en) 5-azaindazole derivatives as adenosine receptor antagonists
PT3625221T (pt) Derivados de 3-metil-pirrolidino-2,5-diona úteis como antagonistas do recetor de cgrp
GB2582924B (en) Boring device
GB201805675D0 (en) Compounds For Use As Apelin Receptor Antagonists
CA186963S (en) Agricultural chemical refilling machine
HK40029095A (en) Heterocyclic compounds as adenosine antagonists
GB201817943D0 (en) Galanin-2 receptor agonists
HK40043168A (en) Heterocyclic p2y14 receptor antagonists